New eczema drug shows promise in early trial
NCT ID NCT04643457
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called UCB9741 in healthy volunteers and people with moderate-to-severe atopic dermatitis (eczema). The goal was to check its safety and see if it can improve eczema symptoms. The trial involved 107 participants and compared the drug to a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UCB9741
What this could lead to
If it works, this could lead to a new treatment option for people with moderate-to-severe eczema.
What could go wrong
This is an early-phase trial with only 107 participants, so results may not apply to everyone. The drug may not prove effective or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Up0089 101
London, United Kingdom
-
Up0089 103
Manchester, United Kingdom
-
Up0089 104
Liverpool, United Kingdom
-
Up0089 201
Leiden, Netherlands
-
Up0089 301
Sofia, Bulgaria
-
Up0089 303
Pleven, Bulgaria
-
Up0089 304
Sofia, Bulgaria
-
Up0089 407
Berlin, Germany
-
Up0089 408
Heidelberg, Germany
-
Up0089 410
Leipzig, Germany